The Immunotherapy Series, Part Three: Policy and the FDA

Written By Kenny Kane

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/83adb07f-19f8-4304-a762-67469bca21b3.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] The Immunotherapy Series, Part Three: Policy and the FDA

Immunotherapy and Policy. How can the FDA evolve to help advance and support novel approaches to medicine? How does the field of immune-driven diagnostics serve as a case in point for the need for evolution in existing regulatory frameworks?


Special guests:

Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation


Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope


This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous

Resilience: Craig DeLarge on Digital Mental Health in the Era of COVID-19
Next

The Immunotherapy Series, Part Two: Beyond Immunotherapy